Professional development Vacancies

Updated safety information on COVID-19 vaccines

14.11.2022 1847 views

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has published an update of safety information on the use of COVID-19 vaccines.

EMA confirms that the benefits of using COVID-19 vaccines outweigh the risks of adverse reactions recorded after their use, taking into account the risk of the disease and related complications, including hospitalization and death.

Comirnaty

It is recommended to reflect in the instructions for medical use that the risk of myocarditis and pericarditis in children aged 5 to 11 years is lower than in children aged 12 to 17 years.

Myocarditis and pericarditis

Update of the instructions for medical use

In December 2021, PRAC concluded that the risk of myocarditis and pericarditis after vaccination with Comirnaty is higher in young men, especially after the second vaccination (see the safety information of December 2021). Overall, there is a very rare risk of myocarditis and pericarditis after vaccination with Comirnaty regardless of the dose.

PRAC continued to monitor this risk and evaluated the latest data, including a study conducted in the USA that analyzed data from three safety monitoring systems. Based on this new information, PRAC recommended updating the instructions for medical use in the EU to state that the risk of myocarditis and pericarditis is lower in children aged 5 to 11 years than in children aged 12 to 17 years. The overall frequency category of myocarditis/pericarditis is already reflected in the instructions for medical use as “Very rare” (i.e., occurring in fewer than 1 per 10 000 vaccinated individuals).

Heavy menstrual bleeding

Update of the instructions for medical use

The PRAC has completed the evaluation of cases of heavy menstrual bleeding and recommended adding the adverse reaction “Heavy menstrual bleeding” with the frequency “Not known” to the instructions for medical use.

The conclusion was based on evidence, including cases reported in clinical trials, observational studies, enhanced post-registration surveillance, and spontaneous reports from patients and healthcare professionals, including from EudraVigilance.

The assessment included almost 9 000 reports from around the world of heavy menstrual bleeding with the use of Comirnaty or Spikevax vaccines (both mRNA vaccines).

Cases of heavy menstrual bleeding were reported after the first, second, and booster doses. In a small number of cases, a positive rechallenge test was observed, where heavy menstrual bleeding occurred after the primary vaccination and recurred after the second dose was administered. This may indicate that the medicinal product could have caused the corresponding adverse reaction.

The available data that were reviewed related to cases that were mostly non-serious and transient.

After reviewing the available data, PRAC concluded that there is at least a reasonable possibility that the occurrence of heavy menstrual bleeding has a causal relationship with the use of the vaccine and therefore recommended updating the instructions for medical use.

Menstrual cycle disorders are generally quite a common phenomenon and can occur for many reasons.

There is no evidence that changes in the menstrual cycle observed in some people after vaccination have any effect on fertility. As for the effect of COVID-19 vaccination on pregnancy in general, several studies covering about 65 000 pregnancies at various stages did not reveal any signs of an increased risk of pregnancy complications, miscarriages, preterm births or adverse outcomes in unborn children after vaccination with mRNA COVID-19 vaccines.

PRAC will continue to monitor cases of heavy menstrual bleeding and will report new recommendations in the future if they are justified.

Spikevax

Myocarditis and pericarditis

Update of the instructions for medical use

In December 2021, the PRAC concluded that the risk of myocarditis and pericarditis after Spikevax vaccination is higher in young men, especially after the second vaccination (see the safety information from December 2021).

The instructions for medical use have been updated to reflect that the risk of myocarditis and pericarditis is similar after the second and third doses, as “Very rare” (i.e., occurring in fewer than 1 in 10 000 vaccinated individuals).

Extensive swelling of the limb into which the injection was administered

Update of the instructions for medical use

Based on the PRAC assessment, extensive swelling of the injected limb will be included in the instructions for medical use in the EU as an adverse reaction with the frequency “not known”, since, as a rule, it is difficult to reliably estimate the frequency of adverse reactions based on spontaneous reports (more than 3200 cases in the EU/EEA were reported to EudraVigilance by May 2, 2022). As a rule, spontaneous reports from patients or healthcare professionals concern suspected adverse effects observed after vaccination, but which are not necessarily associated with or caused by the vaccine. In general, extensive swelling of the injected limb is a condition that does not require treatment and resolves within a few days.

Heavy menstrual bleeding

Update of the instructions for medical use

The PRAC has completed the evaluation of cases of heavy menstrual bleeding and recommended adding the adverse reaction “Heavy menstrual bleeding” with the frequency “Not known” to the instructions for medical use.

The conclusion was based on evidence, including cases reported in clinical trials, observational studies, enhanced post-registration surveillance, and spontaneous reports from patients and healthcare professionals, including from EudraVigilance.

The assessment included almost 9 000 reports from around the world of heavy menstrual bleeding with the use of Comirnaty or Spikevax vaccines (both mRNA vaccines).

Cases of heavy menstrual bleeding were reported after the first, second, and booster doses. In a small number of cases, a positive rechallenge test was observed, where heavy menstrual bleeding occurred after the primary vaccination and recurred after the second dose was administered. This may indicate that the medicinal product could have caused the corresponding adverse reaction.

The available data that were reviewed related to cases that were mostly non-serious and transient.

After reviewing the available data, PRAC concluded that there is at least a reasonable possibility that heavy menstrual bleeding is causally related to the use of the vaccine and therefore recommended updating the instructions for medical use.

Menstrual cycle disorders are generally quite a common phenomenon and can occur for many reasons.

There is no evidence that changes in the menstrual cycle observed in some people after vaccination have any effect on fertility. As for the effect of COVID-19 vaccination on pregnancy in general, several studies covering about 65 000 pregnancies at various stages did not reveal any signs of an increased risk of pregnancy complications, miscarriages, preterm births or adverse outcomes in unborn children after vaccination with mRNA COVID-19 vaccines.

PRAC will continue to monitor cases of heavy menstrual bleeding and will report new recommendations in the future if they are justified.

Urticaria

Update of the instructions for medical use

PRAC completed its assessment of the manifestation of a hypersensitivity reaction in the form of urticaria with the use of Spikevax. PRAC concluded that there is a causal relationship between the development of urticaria and the use of the vaccine and therefore recommended updating the information for medical use.

Jcovden (formerly COVID-19 Vaccine Janssen)

Facial nerve paralysis

Update of the instructions for medical use

PRAC completed its evaluation with a recommendation to update the instructions for medical use by adding the adverse reaction “facial paralysis” (including Bell’s palsy). Based on clinical trial data, the frequency of this adverse reaction is “Rare” (i.e., occurring in fewer than 1 in 1000 persons).

The original text of the publication can be found at the link:

LINK LINK LINK LINK